Date: 2017-11-28
Type of information: Development agreement
Compound: synthetic gene promoters
Company: Synpromics (UK) UCL (UK)
Therapeutic area: Neurodegenerative diseases
Type agreement: research - development - R&D
Action mechanism:
Disease: Parkinson's disease
Details:
- • On November 28, 2017, Synpromics announced a new collaboration with UCL to generate a range of synthetic gene promoters for the central nervous system (CNS), to develop a gene therapy for Parkinson’s disease. The joint project will see the company develop novel gene promoters that specifically control the expression of therapeutic genes in different sub-populations of neurones. In the first instance, UCL will use these new gene switches to develop a gene therapy-based approach for the treatment of Young-Onset Parkinson’s disease. The collaboration is expected to last over 24 months with work being split equally between the two partners.
Financial terms:
Latest news:
Is general: Yes
